An Open Label, Phase 1b, Ascending Dose Study of DM199

NCT02868996 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Stroke

Interventions

DRUG: Recombinant human tissue kallikrein

Sponsor

DiaMedica Therapeutics Inc

Collaborators

[object Object]